Castle Biosciences expects preliminary full-year 2025 revenue of $340 million, above prior guidance, driven by a 37% year-over-year increase in test reports. The Friendswood, Texas firm delivered strong volumes for DecisionDx‑Melanoma and TissueCypher Barrett’s Esophagus tests, which together were core fourth-quarter revenue drivers and rose 42% year over year in Q4. The company also reported solid cash and marketable securities balances, supporting continued commercial investment in its diagnostic portfolio.